Winona Company Overview & Business Model: Is It Legit?

What Is Winona and How Does Its Business Model Work?

Winona is a direct-to-consumer telehealth company founded to address the persistent undertreatment of menopause symptoms in the United States. The platform operates on a cash-pay, subscription-adjacent model: patients pay an initial consultation fee, receive an asynchronous or synchronous physician evaluation, and then pay monthly for any prescribed medications delivered to their door.

The Cash-Pay Telehealth Structure

Unlike insurance-based primary care, Winona charges out-of-pocket at every step. That model has real trade-offs. Patients skip prior-authorization delays and formulary restrictions, which can be meaningful for hormones that insurers frequently exclude or restrict. The downside is that costs are entirely the patient's responsibility, with no partial reimbursement unless the patient has an HSA or FSA account (Winona receipts are typically HSA/FSA eligible).

The company does not bill Medicare or Medicaid. For context, a 2023 analysis published in Menopause found that out-of-pocket spending on menopause-related care averages $1,300 to $2,800 per year across insurance types, suggesting cash-pay platforms can be cost-competitive for patients with high-deductible plans [1].

Physician Oversight and State Licensing

Every prescription issued through Winona must come from a U.S.-licensed physician practicing in the patient's state. That requirement is not optional: federal law under the Ryan Haight Online Pharmacy Consumer Protection Act mandates at least one in-person or synchronous telemedicine evaluation before prescribing certain controlled substances, and state medical boards independently regulate prescribing standards [2]. Winona uses asynchronous intake forms supplemented by synchronous follow-up when clinically indicated.

Compounding Pharmacy Relationships

Winona partners with 503A compounding pharmacies. These pharmacies operate under state board of pharmacy oversight and must comply with USP General Chapter 795 (non-sterile) or 797 (sterile) standards, though they are not subject to the same pre-market approval requirements as FDA-approved drug manufacturers [3]. Patients should understand that compounded products lack FDA-approved labeling and have not undergone the same efficacy trials as branded or generic equivalents.

What Does Winona Prescribe?

Winona's formulary centers on hormones used in menopause management. That scope is narrow by design.

Estrogen and Progesterone

The core of Winona's prescribing is estradiol (available as transdermal cream, patch equivalents via compounding, and oral forms) combined with progesterone for patients with an intact uterus. The clinical rationale is well-established. The 2022 North American Menopause Society (NAMS) position statement states: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause" [4]. NAMS recommends that progesterone be added to estrogen therapy in women with a uterus to protect the endometrium from hyperplasia.

Bioidentical estradiol (17-beta-estradiol) has the same molecular structure as endogenous human estrogen. FDA-approved bioidentical options include Vivelle-Dot, Climara, and generic estradiol patches. Winona may prescribe compounded versions of these molecules, which carry the caveats above.

Testosterone and DHEA

Winona also prescribes compounded testosterone for women reporting low libido and fatigue. Female androgen insufficiency is a recognized clinical entity, though the FDA has not approved any testosterone product specifically for women in the United States [5]. The Endocrine Society's 2019 clinical practice guideline recommends testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD) after other causes are excluded, at doses producing physiological premenopausal levels [5]. DHEA (dehydroepiandrosterone) in vaginal form is FDA-approved as Intrarosa for dyspareunia; compounded oral DHEA carries less evidence.

What Winona Does Not Prescribe

Winona does not offer GLP-1 agonists, thyroid medications, contraceptives, or primary care services. That specialization keeps clinical scope tight but means patients with overlapping conditions (obesity, thyroid disease) must maintain separate care relationships.

Is Winona Legit? Assessing the Safety and Evidence Base

The legitimacy question has two layers: Is the company operating lawfully, and is the medicine it offers supported by evidence?

Legal and Regulatory Standing

Winona operates within the legal framework for telehealth prescribing. Physicians are licensed in the states where patients reside, and compounding pharmacies must hold state licensure. No FDA warning letters or FTC enforcement actions against Winona appear in publicly accessible databases as of this writing. The company is not accredited by the National Committee for Quality Assurance (NCQA), but NCQA accreditation is voluntary and not required for telehealth prescribers.

Clinical Evidence for HRT

The evidence base for HRT is substantial and increasingly favorable after years of controversy following the 2002 Women's Health Initiative (WHI). The WHI initially reported increased risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism with combined estrogen-progestin therapy [6]. Subsequent re-analysis showed that those risks were concentrated in older, symptomatic women initiating therapy more than 10 years after menopause, not in women aged 50 to 59 initiating therapy near menopause onset [7].

The "timing hypothesis," now supported by the 2022 NAMS position statement and an extensive Cochrane review (69 trials, N=40,410), holds that HRT initiated within 10 years of menopause or before age 60 carries a favorable benefit-risk profile for most healthy women [4, 8]. Specifically, the Cochrane analysis found that HRT reduced vasomotor symptoms by approximately 75% compared to placebo and improved sleep, mood, and quality of life scores [8].

Those data support the medicine Winona delivers. They do not, however, validate Winona's specific compounding formulations, dosing protocols, or follow-up standards, none of which have been published in peer-reviewed literature.

Absence of Published Outcomes Data

Winona has published no cohort data, no retrospective outcomes analysis, and no prospective trial. That is common for direct-to-consumer telehealth companies but should be noted. Patients and clinicians cannot evaluate whether Winona's prescribing patterns match guideline-concordant care without transparency data.

The HealthRX Medical Team developed a five-factor framework for evaluating DTC hormone telehealth platforms: (1) physician licensure verification, (2) compounding pharmacy USP compliance documentation, (3) baseline lab requirements before prescribing, (4) follow-up visit cadence, and (5) published or auditable outcomes data. Winona meets criteria 1 and partially meets criteria 2 and 4. It does not publicly document criteria 3 or 5, which places it below the standard of a full in-person menopause specialist practice but comparable to most competing telehealth platforms.

Winona Pricing: What Does It Actually Cost?

Consultation and Subscription Fees

Winona charges approximately $35 for the initial asynchronous consultation with a physician. Monthly medication costs range from roughly $75 to $149 depending on whether the patient receives an FDA-approved generic or a compounded formulation. Testosterone and DHEA add to the monthly total. Over 12 months, a patient on estradiol plus progesterone could spend $960 to $1,800 in medication costs alone, not counting consultation renewals.

Comparison to Insurance-Covered Alternatives

Generic estradiol patches (e.g., 0.05 mg/24 hr, 8-patch supply) retail at major pharmacies for approximately $25 to $60 per month without insurance and are often covered under Part D or commercial plans with a modest copay. Generic oral micronized progesterone (Prometrium equivalent) runs $20 to $45 per month at GoodRx pricing. Patients who can access a gynecologist or primary care physician willing to prescribe these generics may pay significantly less total out-of-pocket than Winona's compounded equivalents.

That price differential matters. FDA-approved generic estradiol has an identical molecular structure to compounded bioidentical estradiol and the same clinical evidence behind it. Patients paying a premium for "bioidentical" compounded products from Winona should understand they are paying for convenience and access, not for a pharmacologically superior product.

Winona vs. Alternatives: How Does It Compare?

Winona vs. Midi Health

Midi Health positions itself similarly as a menopause-focused telehealth platform but accepts insurance in some states. Midi's physician network includes menopause-certified practitioners, a credential offered by NAMS that Winona does not publicly advertise for its prescriber roster. For patients with commercial insurance, Midi may reduce net cost substantially.

Winona vs. Alloy Women's Health

Alloy also focuses on menopause and prescribes FDA-approved estradiol and progesterone as its primary formulations rather than compounded alternatives. That distinction is clinically meaningful: FDA-approved products have standardized manufacturing quality controls. Alloy's pricing is roughly comparable to Winona's, and it has received positive coverage in peer-reviewed commentary on menopause telehealth access.

Winona vs. Traditional Gynecology

A board-certified gynecologist or a NAMS-certified menopause practitioner can prescribe the same FDA-approved hormones, order baseline labs (FSH, estradiol, lipid panel, mammography review), and monitor therapy longitudinally. The Endocrine Society and NAMS both recommend baseline and follow-up laboratory assessment before and during hormone therapy [5, 4]. Winona's intake process does not consistently require lab work before prescribing, which is a clinical gap compared to specialist-level care.

When Winona Makes Sense

Winona fills a real access gap. A 2020 survey published in Menopause found that only 20% of ob-gyn residency programs provide comprehensive menopause training, contributing to a national shortage of menopause-literate clinicians [9]. For a patient in a rural area with no local gynecologist willing to prescribe HRT, Winona represents an accessible option backed by real physician oversight, even if that oversight is less intensive than specialist care.

What Lab Work Does Winona Require?

Winona's intake process relies primarily on symptom questionnaires and medical history rather than mandatory serum hormone levels. The NAMS 2022 position statement notes that menopause is a clinical diagnosis in women aged 45 to 55 with characteristic symptoms, and routine FSH or estradiol levels are not required to begin therapy in this population [4]. That gives Winona some clinical cover for prescribing without baseline labs.

For younger patients (age <45) or those with atypical presentations, the absence of mandatory FSH testing is a more significant gap. Premature ovarian insufficiency (POI), defined as ovarian failure before age 40, affects approximately 1% of women and requires a confirmed FSH >25 IU/L on two measurements 4 weeks apart before treatment decisions [10]. A purely symptom-based intake process could miss or mismanage POI in younger patients.

Patient Experience and Reviews: What the Data Show

Reported Satisfaction

Winona carries a 4.2 out of 5 rating on Trustpilot based on several hundred reviews as of early 2025, with patients most commonly citing physician responsiveness and medication delivery speed as positives. Negative reviews cluster around customer service delays, shipping issues, and perceived difficulty adjusting prescriptions.

What Reviews Cannot Tell You

Patient satisfaction scores do not measure clinical outcomes. A patient feeling better on a compounded hormone regimen is meaningful, but it does not confirm that the formulation is dosed correctly, bioavailable as labeled, or safe relative to a monitored FDA-approved equivalent. The FDA has issued guidance noting that compounded drugs "have not been evaluated for safety, effectiveness, or quality before they are marketed" [3].

Safety Considerations and Contraindications

HRT is not appropriate for all patients. NAMS and the American College of Obstetricians and Gynecologists (ACOG) list the following as absolute or strong contraindications: unexplained vaginal bleeding, known or suspected estrogen-sensitive breast or endometrial cancer, active thromboembolic disease, active liver disease, and known thrombophilic conditions [4, 11].

Winona's intake forms screen for these contraindications, but asynchronous screening cannot substitute for a physical examination or a review of imaging and pathology results. Patients with complex medical histories, prior breast cancer, or thrombosis history should consult an in-person specialist before initiating HRT through any telehealth platform.

The absolute risk increase for breast cancer with combined estrogen-progestin therapy in the WHI was 8 additional cases per 10,000 women per year, a figure that should be communicated clearly to patients [6]. Estrogen-alone therapy in women without a uterus showed no significant breast cancer risk increase at 7 years in the same trial [6].

Is Winona Worth It? A Clinical Perspective

For a perimenopausal or postmenopausal woman aged 45 to 60 with moderate-to-severe vasomotor symptoms, no contraindications, and limited access to a menopause-literate physician, Winona offers real clinical value. The hormones it prescribes work. The Menopause Hormone Therapy Trial within the WHI showed that estrogen-progestin therapy reduced hot flash frequency by 75% at 1 year versus placebo [6], a magnitude replicated across dozens of subsequent trials.

The premium paid over generic pharmacy prices buys convenience and access, not superior pharmacology. Patients who can access a gynecologist and afford a $25-per-month generic patch-and-pill regimen may find Winona unnecessary. Patients who cannot get an appointment for 6 months, who have been dismissed by prior providers, or who live in regions with few menopause-trained clinicians may find it money well spent.

The clinical floor here is: confirm no contraindications exist, obtain baseline labs at least once (even through a separate PCP visit), and plan for annual follow-up with a clinician who can perform a physical examination. The Endocrine Society recommends reassessing hormone therapy at least annually, adjusting dose to the lowest effective amount, and reviewing cardiovascular and breast cancer risk at each visit [5].